An innovative approach for the characterization of the isoforms of a monoclonal antibody product

mAbs

Volumn 3, Issue 6, 2011, Pages 505-512

  Sundaram, Shanmuuga ^a,b,c   Matathia, Alice ^a,b,c   Qian, Jun ^a,b,c   Zhang, Jingming ^a,b,c   Hsieh, Ming Ching ^a,b,c   Liu, Tun ^a,b,c   Crowley, Richard ^a,b,c   Parekh, Babita ^a,b,c   Zhou, Qinwei ^a,b,c  

^a Bioanalytical Science   (United States)

^b ImClone Systems Inc   (United States)

^c ELI LILLY AND COMPANY   (United States)

Author keywords

Charge heterogeneity; Glycosylation; IgG1; Isoforms; Monoclonal antibody; Silaic acid

Indexed keywords

IMMUNOGLOBULIN G1; LYSINE; SIALIDASE; CARBOXYPEPTIDASE; IMMUNOGLOBULIN G; ISOPROTEIN; MONOCLONAL ANTIBODY; N ACETYLNEURAMINIC ACID;

ARTICLE; DRUG ACTIVITY; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; BIOTECHNOLOGY; CHEMISTRY; EVALUATION; HUMAN; METABOLISM; METHODOLOGY;

ANTIBODIES, MONOCLONAL; BIOTECHNOLOGY; CARBOXYPEPTIDASES; CHROMATOGRAPHY, LIQUID; HUMANS; IMMUNOGLOBULIN G; LYSINE; MASS SPECTROMETRY; N-ACETYLNEURAMINIC ACID; NEURAMINIDASE; PROTEIN ISOFORMS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 81255211544     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.4161/mabs.3.6.18090     Document Type: Article

References (40)

1. Brekke OH, Sandlie I. Therapeutic antibodies for human diseases at the dawn of the twenty-first century. Nat Rev Drug Discov 2003; 2:52-62; PMID:12509759; DOI:10.1038/nrd984.
2. Bebbington C, Yarranton G. Antibodies for the treatment of bacterial infections: current experience and future prospects. Curr Opin Biotechnol 2008; 19:613-9; PMID:19000762; DOI:10.1016/j.copbio.2008.10.002.
3. Aires da Silva F, Corte-Real S, Goncalves J. Recombinant antibodies as therapeutic agents: pathways for modeling new biodrugs. BioDrugs 2008; 22:301-14; PMID:18778112.
4. Jefferis R, Lund J, Mizutani H, Nakagawa H, Kawazoe Y, Arata Y, et al. A comparative study of N-linked oligosaccharide structures of human IgG subclass proteins. Biochem J 1990; 268:529-37; PMID:2363690.
5. Jefferis R, Lund J. Glycosylation of antibody molecules. Structural and functional significance. Chem Immunol 1997; 65:111-28; PMID:9018875; DOI:10.1159/000319352.
6. Manning MC, Patel K, Borchardt R. Stability of protein pharmaceuticals. Pharm Res 1989; 6:903-18; PMID:2687836; DOI:10.1023/A:1015929109894.
7. Volkin DB, Mach H, Middaugh CR. Degradative covalent reactions important to protein stability. Mol Biotechnol 1997; 8:105-22; PMID:9406181.
8. United States Food and Drug Administration. Points to consider in the manufacture and testing of monoclonal antibody products for human use. US department of Health and Human services, FDA Center for Biologics Evaluation and Research, February 28, 1997.
9. Reichert JM. Antibody-based therapeutics to watch in 2011. MAbs 2011; 3:76-99; PMID:21051951; DOI:10.4161/mabs.3.1.13895.
10. Reichert JM. Metrics for antibody development. MAbs 2010; 2:695-700; PMID:20930555; DOI:10.4161/mabs.2.6.13603.
11. Lansigan F, Foss FM. Current and emerging treatment strategies for cutaneous T-cell lymphoma. Drugs 2010; 70:273-86; PMID:20166766; DOI:10.2165/11532190.
12. Eggermont AM, Robert C. New drugs in melanoma: It's whole new world. Eur J Cancer 2011; 47:2150-7; PMID:21802280; DOI:10.1016/j.ejca.2011.06.052.
13. Vlasak J, Ionescu R. Heterogeneity of monoclonal antibodies revealed by charge sensitive methods. Curr Pharm Biotechnol 2008; 9:468-81; PMID:19075686; DOI:10.2174/138920108786786402.
14. Meert CD, Brady LJ, Guo A, Balland A. Characterization of antibody charge heterogeneity resolved by preparative immobilized pH gradients. Anal Chem 2010; 82:3510-8; PMID:20364842; DOI:10.1021/ac902408r.
15. Hooker AD, Goldman MH, Markham MH, James DC, Ison AP, Bull AT, et al. N-glycans of recombinant human interferon-gamma change during batch culture of Chinese hamster ovary cells. Biotechnol Bioeng 1995; 48:639-48; PMID:18623533; DOI:10.1002/bit.260480612.
16. Gu X, Xie L, Harmon BJ, Wang DI. Influence of Primatone RL supplementation on sialylation of recombinant human interferon-gamma produced by Chinese hamster ovary cell culture using serum-free media. Biotechnol Bioeng 1997; 56:353-60; PMID:18642238; DOI:10.1002/(SICI)1097-0290(19971120)56:4353:: AID-BIT13.0.CO;2-N.
17. Patel TP, Parkeh RB, Moellering BJ, Prior CP. Different culture methods lead to differences in glycosylation of a murine IgG monoclonal antibody. Biochem J 1992; 285:839-45; PMID:1497622.
18. Fang Y, Dumont L, Larsen B. Real time isoform analysis by two dimensional chromatography of a monoclonal antibody during bioreactor fermentations. J Chromatogr A 1998; 816:39-47; PMID:9741099; DOI:10.1016/S0021-9673(98)00032-6.
19. Kroon DJ, Baldwin-Ferro A, Lalan L. Identification of sites of degradation in a therapeutic monoclonal antibody by peptide mapping. Pharm Res 1992; 9:1386-93; PMID:1475223; DOI:10.1023/A:1015894409623.
20. Bornstein P, Balian G. Cleavage at Asn-Gly bonds with hydroxylamine. In: Hirs CHW, Serge N, Timasheff N, Editors. Methods in Enzymol. Vol XLVIII, Enzyme Structure (Part E), Academic Press, New York 1997.
21. Stephenson RC, Clarke S. Succimide formation from aspartyl and asparaginal peptides as a model for spontaneous degradation of proteins. J Biol Chem 1989; 264:6164-70; PMID:2703484.
22. Perkins M, Theiler R, Lunte S, Jeschke M. Determination of the origin of charge heterogeneity in a murine monoclonal antibody. Pharm Res 2000; 17:1110-7; PMID:11087044; DOI:10.1023/A:1026461830617.
23. Clarke S. Propensity for spontaneous succinimide formation from aspartyl and asparaginyl residues in cellular proteins. Int J Pept Protein Res 1987; 30:808-21; PMID:3440704; DOI:10.1111/j.1399-3011.1987.tb03390.x.
24. Kossiakoff AA. Tertiary structure is a principal determinant to protein deamidation. Science 1988; 240:191-4; PMID:3353715; DOI:10.1126/science.3353715.
25. Tyler-Cross R, Schirch V. Effects of amino acid sequence, buffers and ionic strength on the rate and mechanism of deamidation of asparagines residues in small peptides. J Biol Chem 1991; 266:22549-56; PMID:1939272.
26. Zhang W, Czuprryn M. Analysis of isoaspartate in a recombinant monoclonal antibody and its charge isoforms. J Pharm Biomed Anal 2003; 30:1479-90; PMID:12467919; DOI:10.1016/S0731-7085(02)00479-X.
27. Harris RJ. Processing of C-terminal lysine and arginine residues of proteins isolated from mammalian cell culture. J Chromatogr A 1995; 705:129-34; PMID:7620566; DOI:10.1016/0021-9673(94)01255-D.
28. Tous GI, Wei Z, Feng J, Bilbulin S, Bowen S, Smith J, et al. Characterization of a novel modification to monoclonal antibodies: thioether cross-link of heavy and light chains. Anal Chem 2005; 77:2675-82; PMID:15859580; DOI:10.1021/ac0500582.
29. Cohen SL, Price C, Vlasak J. β-elimination and peptide bond hydrolysis: two distinct mechanisms of human IgG1 hinge fragmentation upon storage. J Am Chem Soc 2007; 129:6976-7; PMID:17500521; DOI:10.1021/ja0705994.
30. Pristatsky P, Cohen SL, Krantz D, Acevedo J, Ionescu R, Vlasak J. Evidence for trisulfide bonds in a recombinant vaient of human IgG2 monoclonal antibody. Anal Chem 2009; 81:6148-55; PMID:19591437; DOI:10.1021/ac9006254.
31. Rush RS, Derby PL, Smith DM, Merry C, Rogers G, Rhode MF. Micro-hertogeneity of erythropoietin carbohydrate structure. Anal Chem 1995; 67:1442-52; PMID:7741215; DOI:10.1021/ac00104a022.
32. Catlin DH, Breidbach A, Elliot S, Glaspy J. Comparison of isoelectric patterns of Darbepoeetin Alfa, recombinant erythropoietin and endogeneous erythropoietin from human urine. Clin Chem 2002; 11:2057-9. (Pubitemid 35222769)
33. Qian J, Liu T, Yang L, Daus A, Crowley R, Zhou Q. Structural characterization of N-linked oligosaccharides on monoclonal antibody cetuximab by the combination of orthogonal matrix-assisted lase desorption/ ionization hybrid quadrupole-quadrupole time-of-fight tandem mass spectrometry and sequential enzymatic digestion. Anal Biochem 2007; 364:8-18; PMID:17362871; DOI:10.1016/j.ab.2007.01.023.
34. Natsume A, Niwa R, Satoh M. Improving effector functions of antibodies for cancer treatment: Enhancing ADCC and CDC. Drug Des Devel Ther 2009; 3:7-16; PMID:19920917.
35. Peipp M, Lammerts JJ, van Bueren L, Schneider-Merck TJ, Bleeker WWK, Dechant M, et al. Antibody fucosylation differently impacts cytotoxicity mediated by NK and PMN effector cells. Blood 2008; 112:2390-9; PMID:18566325; DOI:10.1182/blood-2008-03-144600.
36. Kaneko Y, Nimmerijahn F, Ravetch JV. Anti inflammatory activity of immunoglobulin G resulting from Fc sialyation. Science 2006; 313:670-3; PMID:16888140; DOI:10.1126/science.1129594.
37. Scallon BJ, Tam SH, McCarthy SG, Cai AN, Raju TS. Higher levels of sialyated Fc glycans in immunoglobulin G molecules can adversely impact functionality. Mol Immunol 2007; 44:1524-34; PMID:17045339; DOI:10.1016/j. molimm.2006.09.005.
38. Naso MF, Tam SH, Scallon BJ, Raju TS. Engineering host cell lines to reduce terminal sialyation of secreted antibodies. MAbs 2010; 2:519-27; PMID:20716959; DOI:10.4161/mabs.2.5.13078.
39. Shinkawa T, Nakamura K, Yamane N, Shoji-Hosaka E, Kanda Y, Sakurada M, et al. The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody dependent cellular cytotoxicity. J Biol Chem 2003; 278:3466-73; PMID:12427744; DOI:10.1074/jbc.M210665200.
40. Weinberg W, Fraizer-Jesson MR, Wu WJ, Weir A, Hartsough M, Keegan P, et al. Development and regulation of monoclonal antibody products: Challenges and opportunities. Cancer Metastasis Rev 2005; 24:569-84; PMID:16408162; DOI:10.1007/s10555-005-6196-y.